Search the National Drug Schedules
Search By:
Drug Name or Keyword
Schedule
Footnote
Glossary Search:
Drug Name
Comments
Schedule
Date
When sold in oral, fixed-dose combinations, in package sizes containing either more than 20,000 mg of acetaminophen or more than 6,000 mg of ibuprofen*
*Note that this listing does not apply to products containing ibuprofen that would meet the criteria to be included on the Prescription Drug list, as these would require a prescription
II
Jul / 20
oral preparations containing 80 mg or less per dosage unit and intended for pediatric use or rectal preparations containing 150 mg or less per dosage unit, in package sizes containing no more than 1.92 g of acetylsalicylic acid.
II
Feb / 02
when used for prophylaxis against travellers' diarrhea & due to enterotoxigenic escherichia coli (ETEC)
II
Jan / 04
when sold in a concentration of 0.05% clobetasone butyrate in cream preparations for topical use on the skin
II
Oct / 06
in preparations exempted from the Regulations to the Controlled Drugs and Substances Act
II
Sep / 98
for topical use in concentrations of greater than 2%
II
May / 06
in preparations containing no more than 8 mg per unit dose, with a label recommending no more than 8 mg/dose or 32 mg/day and for use not more than 7 days, and indicated for nasal congestion.
II
Apr / 06
in pre-filled syringes intended for emergency administration by injection in the event of anaphylactic reactions to allergens
II
Sep / 99
When sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg/spray for those 18 years of age and older, in package sizes containing more than 360 metered sprays.
II
Jan / 20
except glycopyrronium bromide, including but not limited to glycopyrrolate, when used orally or for inhalation
II
Dec / 17
except when recommended for injectable use
II
Aug / 16
when sold in concentrations of 1.5 mg or less per oral dosage unit (except when labelled to be taken as a single dose of 1.5 mg and in package sizes containing no more than 1.5 mg levonorgestrel, packaged and labelled for emergency contraception.)
II
May / 15
for ophthalmic or parenteral use, or topical use on mucous membranes, except lozenges
II
Sep / 98
when indicated for emergency use for opioid overdose
Note: Pharmacists should verify whether there is any additional guidance in their jurisdiction regarding the provision of this drug.
II
Feb / 17
when indicated for emergency use for opioid overdose
Note: Pharmacists should verify whether there is any additional guidance in their jurisdiction regarding the provision of this drug.
II
Feb / 17
*Note that this listing does not apply to live herpes zoster vaccines as they have not been specifically reviewed by the NDSAC. Therefore, live herpes zoster vaccines would follow the general vaccine listings.
II
Jul / 21
Footnotes
C – Drug is listed in the Schedule to Part G of the Food and Drug Regulations under the Controlled Drugs and Substances Act
CR – Drug has been recommended for addition to the Controlled Drugs and Substances Act
N – Drug is listed in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
NR – Drug has not been reviewed by the NDSAC
PDL – Drug is listed in the Health Canada Prescription Drug List
TS – Drug is listed in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act